Roberta F.
- Country
- Italy
- Department
- Nefrologia e Dialisi
Research Overview
- A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH IGG4-RELATED DISEASE (INDIGO)
- Phase 2 Open‑Label Study of Subcutaneous Surovatamig (AZD0486) in Adults with Antibody‑Mediated Kidney Disease: Safety, Tolerability, PK and Proteinuria Efficacy
- Phase IIb Randomized Double‑Blind Placebo‑Controlled Study of Eplontersen Plus ALXN2220 Versus Eplontersen + Placebo in Adults with Transthyretin‑Mediated Amyloid Cardiomyopathy
Data & Insights
Has run more than one trial at 142 of 333 partner sites.
Specializations
Nephrology and glomerular disease
Roberta Fenoglio’s clinical research activity is centered on kidney disease, with a strong focus on IgA nephropathy, lupus nephritis, primary membranous nephropathy, focal segmental glomerulosclerosis, and rapidly progressive glomerulonephritis.
- Proteinuria reduction
- Complement-mediated kidney disease
- Renal response and kidney function
Her work also includes end-stage kidney disease, chronic kidney disease, and dialysis-related care.
Autoimmune and systemic inflammatory diseases
Her trial portfolio includes multiple immune-mediated disorders, such as systemic lupus erythematosus, antiphospholipid syndrome, IgG4-related disease, Behçet’s syndrome, dermatomyositis, and eosinophilic granulomatosis with polyangiitis.
- Autoimmune flare control
- Immune suppression strategies
- Renal involvement in systemic disease
She is also involved in studies of immune thrombocytopenia, bullous pemphigoid, and immune-mediated necrotizing myopathy.
HIV and antiretroviral therapy
Another major area of interest is HIV-1 infection, including treatment maintenance, regimen switching, and virologic suppression in adults living with HIV.
- Antiretroviral switch therapy
- Virologic suppression
- Treatment simplification
Her research also extends to chronic hepatitis D virus infection and other viral infections requiring therapeutic innovation.
Cardiovascular, thrombotic, and metabolic disease
Her clinical studies include atherosclerotic cardiovascular disease in patients with end-stage kidney disease, atrial fibrillation after PCI, ischemic stroke prevention, and cardiovascular risk reduction in type 2 diabetes.
- Antithrombotic therapy
- Stroke prevention
- Cardiorenal protection
Her portfolio also includes transthyretin amyloid cardiomyopathy and heart-kidney protection approaches.
Oncology, infectious disease, and dialysis innovation
Her research landscape also reaches colorectal cancer, rectal cancer, oral cavity squamous cell carcinoma, leiomyosarcoma, and diffuse large B-cell lymphoma.
- Solid tumor therapy
- Hematologic malignancy
- Peritoneal dialysis and maintenance dialysis
Additional activity includes tuberculosis, severe viral lung infection, and dialysis solution development.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.